Article
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
Neuron - 24 Apr 2013
Cruchaga Carlos, Kauwe John S K, Harari Oscar, Jin Sheng Chih, Cai Yefei, Karch Celeste M, Benitez Bruno A, Jeng Amanda T, Skorupa Tara, Carrell David, Bertelsen Sarah, Bailey Matthew, McKean David, Shulman Joshua M, De Jager Philip L, Chibnik Lori, Bennett David A, Arnold Steve E, Harold Denise, Sims Rebecca, Gerrish Amy, Williams Julie, Van Deerlin Vivianna M, Lee Virginia M-Y, Shaw Leslie M, Trojanowski John Q, Haines Jonathan L, Mayeux Richard, Pericak-Vance Margaret A, Farrer Lindsay A, Schellenberg Gerard D, Peskind Elaine R, Galasko Douglas, Fagan Anne M, Holtzman David M, Morris John C, Goate Alison M
Abstract excerpt
Cerebrospinal fluid (CSF) tau, tau phosphorylated at threonine 181 (ptau), and Aβ₄₂ are established biomarkers for Alzheimer's disease (AD) and have been used as quantitative traits for genetic analyses. We performed the largest genome-wide association study for cerebrospinal fluid (CSF) tau/ptau levels published to date (n = 1,269), identifying three genome-wide significant loci for CSF tau and ptau: rs9877502...
Read the complete abstract on PubMed